MTRR Inhibitors

Chemical inhibitors of MTRR can employ various mechanisms to disrupt its function. N,N-Dimethylarginine inhibits nitric oxide synthase, which can indirectly inhibit MTRR by fostering an environment of oxidative stress that may impair MTRR's ability to repair and maintain nucleotide sequences. Methotrexate, by targeting dihydrofolate reductase, leads to a decreased availability of methyl donors, which are crucial for the homocysteine methylation cycle where MTRR exercises its function. Similarly, S-Adenosylhomocysteine builds up as a product inhibitor, competing with S-Adenosylmethionine (SAM), the essential methyl donor cofactor for MTRR, effectively inhibiting its methylation capacity.

Heavy metals like Lead(II) acetate and Cadmium chloride exert their inhibitory effects by binding to critical thiol (-SH) groups in enzymes, which could lead to the modification of MTRR's active site or its substrate binding capability, resulting in inhibited function. Arsenic trioxide similarly binds to vicinal thiols, potentially disrupting MTRR's dithiol-dependent mechanism. Ethionine, being a methionine analog, competes with methionine and can disrupt the methylation reactions necessary for MTRR activity. Hydroxyurea and Chloroquine indirectly inhibit MTRR by targeting nucleotide synthesis and repair enzymes, which are processes linked to the folate metabolism and methylation activities where MTRR is involved. Sulfasalazine, by inhibiting enzymes involved in folate synthesis, can decrease the availability of methionine, which is necessary for the methylation cycle that is dependent on MTRR function.